Download het volledig rapport (302 p.) - KCE

KCE reports vol. 6A Prenatale zorg 160
What is the impact of primary prevention on the seroconversion rate during pregnancy and what is the impact of secondary prevention on
the incidence of congenital toxoplasmosis?
Study Ref Population Intervention Outcomes Results Comments Study
type
EL
Foulon 83 11,286 pregnant women in Evaluation of the
Impact of primary Reduction of
Effect of secondary CH 2b
et al.,
12 consecutive years in possibilities for preventing prevention on the seroconversion: 63% (p= prevention was studied
1994
Belgium
congenital toxoplasmosis seroconversion rate 0.013)
in 76 pregnant women
during pregnancy
at risk of delivering a
child with congenital
toxoplasmosis
Breugel
mans
et al.,
2004
23 First study period (1979-
1982): 2986 Belgian pregnant
women
Second study period (1983-
1990):
8300 Belgian pregnant
women
Third period (1991-2001):
16.541 Belgian pregnant
women
First study period:
- Study of the incidence
of seroconversion
during pregnancy
Second study period:
- Study of the incidence
of seroconversion
- Seronegative women
received a written list
of recommendations
on how to avoid a
toxoplasma infection
during pregnancy
Impact of secondary
prevention on the
incidence of
congenital
toxoplasmosis
Incidence of
seroconversion
during pregnancy
Reduction of the
seroconversion in
Additional reduction of the
incidence of congenital
toxoplasmosis: 40%
First period:
20/1403 (1.43%)
seronegative women
seroconverted during
pregnancy
Second period:
19/3605 (0.53%)
seronegative women
seroconverted during
pregnancy
Third period:
8/8492 (0.09%) seronegative
women seroconverted
Secondary prevention
was antibiotic treatment:
pyrimathamine 50mg +
sulfadiazine 3g daily for
3 weeks alternating with
3 weeks of spiramycin
CH 2b